Transitional Cell Carcinoma

Transitional Cell Carcinoma Clinical Study (Dogs)

Locations:

• Overland Park, KS
• Southfield, MI

Study Details

BluePearl pet hospitals in Overland Park and Southfield are participating in a fully-funded study evaluating the safety and preliminary pain management and potential anti-cancer effect of a novel therapy in dogs with bladder transitional cell carcinoma (TCC).

NOTE: Anti-cancer therapies must be discontinued 21 days prior to enrollment. Medications targeted at the treatment of TCC-associated pain, except for CBD and other cannabinoids, are acceptable provided they have been administered for at least 2 weeks prior to enrolling in the study.

For eligibility, dogs must meet the criteria below.

Study Eligibility

• A diagnosis of TCC exclusively associated with the bladder or bladder and prostate (no urethral involvement). Metastasis is acceptable.
• Accompanying lower urinary tract clinical signs associated with bladder cancer.
• Bladder lesion does not prevent the passage of urinary catheter.
• Does not have any underlying disease that will affect the study objectives or patient safety.
• Does not have evidence of hydronephrosis.
• Does not have an active urinary tract infection (dogs presenting for screening will have a urine culture performed prior to enrollment).
• Does not have a urethral obstruction.
• Is not pregnant or lactating.
• Is not participating in another study.

Kansas – Overland Park Participation Contact Dr. Heather Heeb, Adrienne Hagar, or Beth Rogers at (913) 642-9563.

Michigan – Southfield Participation Contact Dr. Angela Kozicki or Ashley Davis at (248) 354-6640.

Utah – Midvale Participation Contact Dr. Katherine Wright or Ashley Harmon-Neilson at (801) 871-0600.